Literature DB >> 17055226

Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis.

Laia Caja1, Conrad Ortiz, Esther Bertran, Miguel M Murillo, M Jesús Miró-Obradors, Evangelina Palacios, Isabel Fabregat.   

Abstract

The transforming growth factor-beta (TGF-beta) regulates hepatocyte growth, inhibiting proliferation and inducing apoptosis. Indeed, escaping from the TGF-beta suppressor actions might be a prerequisite for liver tumour progression. In this work we show that TGF-beta plays a dual role in regulating apoptosis in FaO rat hepatoma cells, since, in addition to its pro-apoptotic effect, TGF-beta also activates survival signals, such as AKT, the epidermal growth factor receptor (EGFR) being required for its activation. TGF-beta induces the expression of the EGFR ligands transforming growth factor-alpha (TGF-alpha) and heparin-binding EGF-like growth factor (HB-EGF) and induces intracellular re-localization of the EGFR. Cells that overcome the apoptotic effects of TGF-beta undergo morphological changes reminiscent of an epithelial-mesenchymal transition (EMT) process. In contrast, TGF-beta does not activate AKT in adult hepatocytes, which correlates with lack of EGFR transactivation and no response to EGFR inhibitors. Although TGF-beta induces TGF-alpha and HB-EGF in adult hepatocytes, these cells show very low expression of TACE/ADAM 17 (TNF-alpha converting enzyme), which is required for EGFR ligand proteolysis and activation. Furthermore, adult hepatocytes do not undergo EMT processes in response to TGF-beta, which might be due, at least in part, to the fact that F-actin re-organization induced by TGF-beta in FaO cells require the EGFR pathway. Finally, results indicate that EGFR transactivation does not block TGF-beta-induced cell cycle arrest in FaO cells, but must be interfering with the pro-apoptotic signalling. In conclusion, TGF-beta is a suppressor factor for adult quiescent hepatocytes, but not for hepatoma cells, where it plays a dual role, both suppressing and promoting carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055226     DOI: 10.1016/j.cellsig.2006.09.002

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  30 in total

1.  Growth factor- and cytokine-driven pathways governing liver stemness and differentiation.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 2.  Age-Related Macular Degeneration and Intracrine Biology: An Hypothesis.

Authors:  Richard N Re
Journal:  Ochsner J       Date:  2016

3.  Protein-tyrosine phosphatase 1B (PTP1B) deficiency confers resistance to transforming growth factor-β (TGF-β)-induced suppressor effects in hepatocytes.

Authors:  Conrad Ortiz; Laia Caja; Esther Bertran; Águeda Gonzalez-Rodriguez; Ángela M Valverde; Isabel Fabregat; Patricia Sancho
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

4.  NADPH oxidase NOX1 controls autocrine growth of liver tumor cells through up-regulation of the epidermal growth factor receptor pathway.

Authors:  Patricia Sancho; Isabel Fabregat
Journal:  J Biol Chem       Date:  2010-06-04       Impact factor: 5.157

Review 5.  Apoptosis in liver carcinogenesis and chemotherapy.

Authors:  Joaquim Moreno-Càceres; Isabel Fabregat
Journal:  Hepat Oncol       Date:  2015-11-11

6.  Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation.

Authors:  Ravikiran Panakanti; Akshay Pratap; Ningning Yang; John S Jackson; Ram I Mahato
Journal:  Biochem Pharmacol       Date:  2010-09-09       Impact factor: 5.858

7.  ERBB receptor activation is required for profibrotic responses to transforming growth factor beta.

Authors:  Mahefatiana Andrianifahanana; Mark C Wilkes; Claire E Repellin; Maryanne Edens; Theodore J Kottom; Rod A Rahimi; Edward B Leof
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

Review 8.  Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

9.  Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.

Authors:  Shizhen Emily Wang; Bin Xiang; Marta Guix; Maria Graciela Olivares; Joel Parker; Christine H Chung; Atanasio Pandiella; Carlos L Arteaga
Journal:  Mol Cell Biol       Date:  2008-07-14       Impact factor: 4.272

Review 10.  A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition.

Authors:  Wenting Xu; Zhen Yang; Nonghua Lu
Journal:  Cell Adh Migr       Date:  2015-08-04       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.